About Us

Revive Therapeutics Ltd. is focused on advancing novel treatments for rare diseases.

 

Revive is advancing developments in rare diseases such as, Cystinuria, which was granted FDA Orphan Drug Status, Wilson's disease and Rett syndrome (partnered with Rettsyndrome.org).

 

Revive is a publicly-traded company listed on the TSX Venture: RVV in Canada and OTCQB: RVVTF in the U.S.

Read more

news

News

December 06, 2016

Revive Therapeutics Ltd. Announces Positive Study Results in Rett Syndrome

Read more
November 24, 2016

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2016

Read more
November 02, 2016

Revive Therapeutics Ltd. Names Dr. David S. Goldfarb, MD, as Principal Investigator for Cystinuria Phase 2 Study

Read more
October 20, 2016

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2016

Read more
August 18, 2016

Revive Completes $1,500,000 Non-Brokered Private Placement

Read more
Newsletter
Corporate presentation